Kyverna Therapeutics
Clinical trials sponsored by Kyverna Therapeutics, explained in plain language.
-
CAR t therapy takes on myasthenia gravis in pivotal trial
Disease control Recruiting nowThis study tests a new treatment called KYV-101, made from a patient's own immune cells, for people with generalized myasthenia gravis that hasn't improved with standard therapies. About 66 participants will receive either KYV-101 or continue their usual immunosuppressive drugs. …
Phase: PHASE2, PHASE3 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 26, 2026 03:09 UTC
-
15-Year safety check for experimental CAR t therapy begins
Knowledge-focused Recruiting nowThis study tracks 70 people who have already received an infusion of KYV-101, a CAR T cell therapy, for autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis. The goal is to watch for delayed side effects, new cancers, or other health problems over up to 15…
Sponsor: Kyverna Therapeutics • Aim: Knowledge-focused
Last updated May 14, 2026 12:06 UTC